PMC:7170415 / 20243-20610
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 294 | 91-101 | Species | denotes | SARS–CoV-2 | Tax:2697049 |
| 295 | 65-74 | Disease | denotes | infection | MESH:D007239 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T87 | 65-74 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T88 | 91-95 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T142 | 0-245 | Sentence | denotes | The development of serologic assays that accurately assess prior infection and immunity to SARS–CoV-2 will be essential for epidemiologic studies, ongoing surveillance, vaccine studies, and potentially for risk assessment of health care workers. |
| T143 | 246-367 | Sentence | denotes | Immunoassays are already on the market in some countries, but their diagnostic accuracy and optimal use remain undefined. |